You just read:

Ibrutinib RESONATE(TM) Data Show Significant Improvements in Progression-Free Survival and Overall Survival in Patients with Relapsed/Refractory Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma Compared to ofatumumab

News provided by

Janssen

31 May, 2014, 12:31 BST